Whitcup S M, Nussenblatt R B
National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
Ann N Y Acad Sci. 1993 Nov 30;696:307-18. doi: 10.1111/j.1749-6632.1993.tb17166.x.
The number of effective drugs for the treatment of autoimmune uveitis has greatly increased over the past 40 years. Many patients previously condemned to blindness can now be successfully treated with new immunosuppressive agents. New targets of the immune system, such as cell adhesion molecules, may offer novel therapeutic approaches for the treatment of inflammatory disease. However, since the catholicon for uveitis is not yet available, the search for new antiinflammatory therapy continues.
在过去40年里，用于治疗自身免疫性葡萄膜炎的有效药物数量大幅增加。许多以前注定会失明的患者现在可以通过新的免疫抑制剂得到成功治疗。免疫系统的新靶点，如细胞黏附分子，可能为炎症性疾病的治疗提供新的治疗方法。然而，由于治疗葡萄膜炎的万灵药尚未问世，寻找新的抗炎疗法的工作仍在继续。
